TICKERNERD
Menu
INOINOHealthcare · Biotechnology

INO Stock Forecast: Inovio Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.18
−2.48% on the day

The 3 Wall Street analysts covering Inovio Pharmaceuticals, Inc. hold a median 12-month price target of $3 — +154.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$122.0M
Ticker Nerd rank
44 / 100
Median analyst target
$3.00
Analysts covering
3
Total return, dividends reinvested
1W
+8.3%
1M
+7.3%
YTD
−32.2%
1Y
−38.2%
From 52W high
−58.9%
From 52W low
+78.8%
$0.66
$2.87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Inovio Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
44 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
73
Revisions
69
Accruals
58
Growth
56
Issuance
52
Volatility
45
Momentum
35
Value
33
Quality
16

Size (73): Smaller than most of the companies we track.

Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26INOHigh $4.00Median $3.00Low $2.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $2.50Median $3.00High $4.00

The green dot is the last close — the median target sits +154.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
13 Aug 2026JefferiesUpgradeBuy$1.80 → $3.00
3 Aug 2026Piper SandlerReiteratesOverweight$6.00 → $4.00
3 Aug 2026Piper SandlerReiteratesOverweight—
1 June 2026HC Wainwright & Co.MaintainsNeutral—
1 June 2026HC Wainwright & Co.MaintainsNeutral$3.00 → $2.50
14 Nov 2025Piper SandlerReiteratesOverweight—
14 Aug 2025HC Wainwright & Co.ReiteratesNeutral—
9 July 2025Piper SandlerInitiatesOverweight—
14 May 2025OppenheimerMaintainsOutperform—
14 May 2025RBC CapitalReiteratesSector Perform—
19 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
19 Mar 2025RBC CapitalMaintainsSector Perform—
14 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform$18
13 Jan 2025HC Wainwright & Co.MaintainsNeutral—
10 Jan 2025JMP SecuritiesReiteratesMarket Outperform—
18 Nov 2024HC Wainwright & Co.MaintainsNeutral—
18 Nov 2024OppenheimerMaintainsOutperform—
15 Nov 2024RBC CapitalMaintainsSector Perform—
4 Oct 2024RBC CapitalMaintainsSector Perform$8.00 → $7.00
12 Aug 2024OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

INO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Inovio Pharmaceuticals, Inc. (INO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 81% of US stocks

Price / sales
1867.2×

Cheaper than 1% of US stocks

Price / book
22.3×

Cheaper than 5% of US stocks

EV / EBITDA
−1.2×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−130000.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−409.9%

Higher than 4% of US stocks

Return on assets
−84.2%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

INO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INOInovio Pharmaceuticals, Inc.$122.0M
44
GNLXGenelux Corp.$121.6M
19
HURATuHURA Biosciences, Inc.$121.4M
17
NAUTNautilus Biotechnology, Inc.$121.3M
55
GUTSFractyl Health, Inc.$123.7M
30
RANIRani Therapeutics Holdings, Inc.$120.0M
64
ANIXAnixa Biosciences, Inc.$124.4M
85

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Inovio Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INO news & analysis

Inovio Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026positive

Inovio Pharmaceuticals reported on its Q2 earnings call that the U.S. Food and Drug Administration has completed several key steps in its review of the company's biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis. The company is continuing preparations for a potential commercial launch of the treatment.

Why it matters — For Inovio watchers, the FDA's progress on the INO-3107 biologics license application signals forward movement in the regulatory review of a key pipeline candidate ahead of a possible commercial launch.

Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

Inovio Pharmaceuticals held its Q2 2026 earnings conference call, and Seeking Alpha published the transcript of that call.

Why it matters — The transcript provides investors with a full record of management's commentary and responses to analyst questions about the company's quarterly performance.

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

PRNewsWire · 12 Aug 2026positive

INOVIO reported its Q2 2026 financial results and highlighted progress on its BLA for INO-3107 to treat RRP, with a PDUFA date of October 30, 2026, and commercial preparations underway. The company also noted positive Phase 3 results for VGX-3100 from its partner ApolloBio and presented data from its DMAb and DPROT programs.

Why it matters — An INO watcher would care because the company is advancing toward a potential product launch for INO-3107, its lead candidate, with an FDA decision expected by late October 2026.

Bet on 5 Top-Ranked Stocks With Rising P/E

Zacks Investment Research · 5 Aug 2026neutral

Zacks Investment Research highlighted five top-ranked stocks with rising P/E ratios, including Inovio Pharmaceuticals, as part of an unconventional investment approach.

Why it matters — INO watchers may note that the stock's inclusion on this list signals it is being identified by a research firm as having an increasing price-to-earnings ratio, which could draw attention from investors following that strategy.

INOVIO to Report Second Quarter Financial Results on August 12, 2026

PRNewsWire · 4 Aug 2026neutral

INOVIO announced that its second quarter 2026 financial results will be released after the market closes on August 12, 2026. The announcement was made on August 4, 2026.

Why it matters — INO watchers would care because the upcoming report will provide the company's second-quarter financial performance details.

FAQ

Frequently asked questions about INO stock

What is the INO stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Inovio Pharmaceuticals, Inc. have a median 12-month price target of $3, with estimates ranging from $2.5 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INO stock a buy right now?

Of the 3 analysts covering Inovio Pharmaceuticals, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Inovio Pharmaceuticals, Inc. 44 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INO?

As at 22 Aug 2026, Inovio Pharmaceuticals, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (73 of 100).

Will INO stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +154.2% from the last close, and Ticker Nerd's factor model ranks Inovio Pharmaceuticals, Inc. 44 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INO stock forecast for 2030?

No analyst covering Inovio Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $4 over the next 12 months.

How has INO stock performed over the past year?

Inovio Pharmaceuticals, Inc. returned -38.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Inovio Pharmaceuticals, Inc. do?

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing DNA medicines for treating and protecting against HPV-related diseases, cancer, and infectious diseases.

What is the latest news on INO?

The most recent item we track (MarketBeat, 13 Aug 2026): "Inovio Pharmaceuticals Q2 Earnings Call Highlights". Inovio Pharmaceuticals reported on its Q2 earnings call that the U.S. Food and Drug Administration has completed several key steps in its review of the company's biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis. The company is continuing preparations for a potential commercial launch of the treatment.

Company

About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing DNA medicines for treating and protecting against HPV-related diseases, cancer, and infectious diseases. The company employs proprietary technology to design DNA plasmids, which function like software that cells can download to produce specific proteins targeting diseases. These plasmids are delivered using investigational CELLECTRA devices, which apply brief electrical pulses via electroporation to facilitate entry into cells without chemical adjuvants, lipid nanoparticles, or viral vectors. This platform enables targeted immunotherapies that stimulate T cells and antibodies for immune responses against cancers and viruses. Inovio Pharmaceuticals, Inc. advances its pipeline through clinical research, focusing on innovative next-generation therapies in these critical therapeutic areas. Headquartered in Pennsylvania, the company plays a significant role in the biotechnology sector by pioneering DNA-based solutions for unmet medical needs.

CEO Dr. Jacqueline E. Shea Ph.D. · 134 employees · United States · https://www.inovio.com